Decreased activity and stability of pyruvate kinase in sickle cell disease: a novel target for mitapivat therapy

Documenti analoghi

• AG-348 (mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and adenosine triphosphate levels over a broad range of PKLR genotypes
  di: Rab, Minke A.E., et al.
  Pubblicazione: (2020)
• Rapid and reproducible characterization of sickling during automated deoxygenation in sickle cell disease patients
  di: Rab, Minke A.E., et al.
  Pubblicazione: (2019)
• Methodological aspects of the oxygenscan in sickle cell disease: A need for standardization
  di: Rab, Minke A.E., et al.
  Pubblicazione: (2019)
• The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model
  di: Matte, Alessandro, et al.
  Pubblicazione: (2021)
• Oxygen gradient ektacytometry‐derived biomarkers are associated with vaso‐occlusive crises and correlate with treatment response in sickle cell disease
  di: Rab, Minke A. E., et al.
  Pubblicazione: (2020)